TherapeuticsMD, Inc.

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 65/100 (HIGH), 0.6 months cash

13F fund flow: neutral, ? institutional managers

45 PubMed publications found for TherapeuticsMD, .

Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium.

Use of serum evaluation of contraceptive and ovarian hormones to assess reduced risk of pregnancy among women presenting for emergency contraception in a multicenter clinical trial.

Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel.

Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.

Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.

Short interest: 0.6% of float, squeeze risk: LOW

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="TXMD">
<p>TherapeuticsMD, Inc. (TXMD) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for TXMD were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0000025743 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22TXMD%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0000025743

TherapeuticsMD, Inc. (TXMD) — BioTechSigns Verified Summary

TherapeuticsMD, Inc. (TXMD) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for TXMD were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0000025743. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22TXMD%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17